Hubbry Logo
Coenzyme Q10Coenzyme Q10Main
Open search
Coenzyme Q10
Community hub
Coenzyme Q10
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Coenzyme Q10
Coenzyme Q10
Coenzyme Q10
View on Wikipedia
from Wikipedia

Coenzyme Q10
Names
Preferred IUPAC name
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
Other names
  • In general: Ubiquinone, coenzyme Q, CoQ, vitamin Q (misnomer: being not required it cannot be a vitamin)
  • This form: ubidecarenone,

Q10, CoQ10 /ˌkoʊˌkjuːˈtɛn/

Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.005.590 Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+ checkY
    Key: ACTIUHUUMQJHFO-UPTCCGCDSA-N checkY
  • InChI=1/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
    Key: ACTIUHUUMQJHFO-UPTCCGCDBK
  • O=C1/C(=C(\C(=O)C(\OC)=C1\OC)C)C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)C
Properties
C59H90O4
Molar mass 863.365 g·mol−1
Appearance yellow or orange solid
Melting point 48–52 °C (118–126 °F; 321–325 K)
insoluble
Pharmacology
C01EB09 (WHO)
Related compounds
Related quinones
 1,4-Benzoquinone
Plastoquinone
Ubiquinol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

Coenzyme Q (CoQ /ˌkoʊkjuː/), also known as ubiquinone, is a naturally occurring biochemical cofactor (coenzyme) and an antioxidant produced by the human body. The human body mainly produces the form known as coenzyme Q10 (CoQ10, ubidecarenone), but other forms exist.[1][2][3] CoQ is used by and found in many organisms, including animals and bacteria. As a result, it can also be obtained from dietary sources, such as meat, fish, seed oils, vegetables, and dietary supplements.[1][2]

CoQ plays a role in mitochondrial oxidative phosphorylation, aiding in the production of adenosine triphosphate (ATP), which is involved in energy transfer within cells.[1] The structure of CoQ10 consists of a benzoquinone moiety and an isoprenoid side chain, with the "10" referring to the number of isoprenyl chemical subunits in its tail.[4][5][6]

Although a ubiquitous molecule in human tissues, CoQ10 is not a dietary nutrient and does not have a recommended intake level, and its use as a supplement is not approved in the United States for any health or anti-disease effect.[1][2]

Biological functions

[edit]
See also: Q cycle

CoQ10 is a component of the mitochondrial electron transport chain (ETC), where it plays a role in oxidative phosphorylation, a process required for the biosynthesis of adenosine triphosphate, the primary energy source of cells.[1][6][7]

CoQ10 is a lipophilic molecule that is located in all biological membranes of human body and serves as a component for the synthesis of ATP and is a life-sustaining cofactor for the three complexes (complex I, complex II, and complex III) of the ETC in the mitochondria.[1][5] CoQ10 has a role in the transport of protons across lysosomal membranes to regulate pH in lysosome functions.[1]

The mitochondrial oxidative phosphorylation process occurs in the inner mitochondrial membrane of eukaryotic cells.[1] This membrane is highly folded into structures called cristae, which increase the surface area available for oxidative phosphorylation. CoQ10 plays a role in this process as an essential cofactor of the ETC located in the inner mitochondrial membrane and serves the following functions:[1][7]

  • electron transport in the mitochondrial ETC, by shuttling electrons from mitochondrial complexes like nicotinamide adenine dinucleotide (NADH), ubiquinone reductase (complex I), and succinate ubiquinone reductase (complex II), the fatty acids and branched-chain amino acids oxidation (through flavin-linked dehydrogenases) to ubiquinol–cytochrome-c reductase (complex III) of the ETC:[1][7] CoQ10 participates in fatty acid and glucose metabolism by transferring electrons generated from the reduction of fatty acids and glucose to electron acceptors;[8]
  • antioxidant activity as a lipid-soluble antioxidant together with vitamin E, scavenging reactive oxygen species and protecting cells against oxidative stress,[1][6] inhibiting the oxidation of proteins, DNA, and use of vitamin E.[1][9]

Biochemistry

[edit]

Coenzymes Q is a coenzyme family that is ubiquitous in animals and many Pseudomonadota,[10] a group of gram-negative bacteria. The fact that the coenzyme is ubiquitous gives the origin of its other name, ubiquinone.[1][2][11] In humans, the most common form of coenzymes Q is coenzyme Q10, also called CoQ10 (/ˌkoʊkjuːˈtɛn/) or ubiquinone-10.[1]

Coenzyme Q10 is a 1,4-benzoquinone, in which "Q" refers to the quinone chemical group and "10" refers to the number of isoprenyl chemical subunits (shown enclosed in brackets in the diagram) in its tail.[1] In natural ubiquinones, there are from six to ten subunits in the tail, with humans having a tail of 10 isoprene units (50 carbon atoms) connected to its benzoquinone "head".[1]

This family of fat-soluble substances is present in all respiring eukaryotic cells, primarily in the mitochondria.[1] Ninety-five percent of the human body's energy is generated this way.[12] Organs with the highest energy requirements—such as the heart, liver, and kidney—have the highest CoQ10 concentrations.[13][14][15][16]

There are three redox states of CoQ: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and fully reduced (ubiquinol).[1] The capacity of this molecule to act as a two-electron carrier (moving between the quinone and quinol form) and a one-electron carrier (moving between the semiquinone and one of these other forms) is central to its role in the electron transport chain due to the iron–sulfur clusters that can only accept one electron at a time and as a free radical–scavenging antioxidant.[1][11]

Deficiency

[edit]

There are two major pathways of deficiency of CoQ10 in humans: reduced biosynthesis, and increased use by the body.[17] Biosynthesis is the major source of CoQ10. Biosynthesis requires at least 15 genes, and mutations in any of them can cause CoQ deficiency.[17] CoQ10 levels also may be affected by other genetic defects (such as mutations of mitochondrial DNA, ETFDH, APTX, FXN, and BRAF, genes that are not directly related to the CoQ10 biosynthetic process).[17] Some of these, such as mutations in COQ6, can lead to serious diseases such as steroid-resistant nephrotic syndrome with sensorineural deafness.[18][19][20]

Assessment

[edit]

Although CoQ10 may be measured in blood plasma, these measurements reflect dietary intake rather than tissue status. Currently, most clinical centers measure CoQ10 levels in cultured skin fibroblasts, muscle biopsies, and blood mononuclear cells.[21] Culture fibroblasts can be used also to evaluate the rate of endogenous CoQ10 biosynthesis, by measuring the uptake of 14C-labeled p-hydroxybenzoate.[22]

CoQ10 is studied as an adjunctive therapy to reduce inflammation in periodontitis.[23]

Statins

[edit]

Although statins may reduce CoQ10 in the blood it is unclear if they reduce CoQ10 in muscle.[24] Evidence does not support that supplementation improves statin side effects.[24][25]

Chemical properties

[edit]

The oxidized structure of CoQ10 is shown below. The various kinds of coenzyme Q may be distinguished by the number of isoprenoid subunits in their side-chains. The most common coenzyme Q in human mitochondria is CoQ10.[1] Q refers to the quinone head and "10" refers to the number of isoprene repeats in the tail. The molecule below has three isoprenoid units and would be called Q3.

Coenzyme Q3

In its pure state, it is an orange-colored lipophile powder and has no taste or odor.[11]

Biosynthesis

[edit]

Biosynthesis occurs in most human tissue. There are three major steps:

  1. Creation of the benzoquinone structure (using phenylalanine or tyrosine, via 4-hydroxybenzoate)
  2. Creation of the isoprene side chain (using acetyl-CoA)
  3. The joining or condensation of the above two structures

The initial two reactions occur in mitochondria, the endoplasmic reticulum, and peroxisomes, indicating multiple sites of synthesis in animal cells.[26]

An important enzyme in this pathway is HMG-CoA reductase, usually a target for intervention in cardiovascular complications. The "statin" family of cholesterol-reducing medications inhibits HMG-CoA reductase. One possible side effect of statins is decreased production of CoQ10, which may be connected to the development of myopathy and rhabdomyolysis. However, the role statins play in CoQ deficiency is controversial. Although statins reduce blood levels of CoQ, studies on the effects of muscle levels of CoQ are yet to come.

Genes involved include PDSS1, PDSS2, COQ2, and ADCK3 (COQ8, CABC1).[27]

Organisms other than humans produce the benzoquinone and isoprene structures from somewhat different source chemicals. For example, the bacteria E. coli produces the former from chorismate and the latter from a non-mevalonate source. The common yeast S. cerevisiae, however, derives the former from either chorismate or tyrosine and the latter from mevalonate. Most organisms share the common 4-hydroxybenzoate intermediate, yet again uses different steps to arrive at the "Q" structure.[28]

Dietary supplement

[edit]

Although neither a prescription drug nor an essential nutrient, CoQ10 is commonly used as a dietary supplement with the intent to prevent or improve disease conditions, such as cardiovascular disorders.[2][29] Despite its significant role in the body, it is not used as a drug to treat any specific disease.[1][2][3]

Nevertheless, CoQ10 is widely available as an over-the-counter dietary supplement and is recommended by some healthcare professionals, despite a lack of definitive scientific evidence supporting these recommendations,[1][3] especially when it comes to cardiovascular diseases.[30]

Regulation and composition

[edit]

CoQ10 is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of any medical condition.[31][32][33][34] However, it is sold as a dietary supplement not subject to the same regulations as medicinal drugs, and is an ingredient in some cosmetics.[35] The manufacture of CoQ10 is not regulated, and different batches and brands may vary significantly.[33]

Research

[edit]

A 2014 Cochrane review found insufficient evidence to make a conclusion about its use for the prevention of heart disease.[36] A 2016 Cochrane review concluded that CoQ10 had no effect on blood pressure.[37] A 2021 Cochrane review found "no convincing evidence to support or refute" the use of CoQ10 for the treatment of heart failure.[38]

A 2017 meta-analysis of people with heart failure taking 30–100 mg/d of CoQ10 found a 31% lower mortality and increased exercise capacity, with no significant difference in the endpoints of left heart ejection fraction.[39] A 2021 meta-analysis found that CoQ10 was associated with a 31% lower all-cause mortality in HF patients.[40] In a 2023 meta-analysis of older people, ubiquinone had evidence of a cardiovascular effect, but ubiquinol did not.[41]

Although CoQ10 has been studied as a potential remedy to treat purported muscle-related side effects of statin medications, the results were mixed. Although a 2018 meta-analysis concluded that there was preliminary evidence for oral CoQ10 reducing statin-associated muscle symptoms, including muscle pain, muscle weakness, muscle cramps, and muscle tiredness,[42] 2015[43] and 2024[30] meta-analysis found that CoQ10 had no effect on statin myopathy.[43][30]

Pharmacology

[edit]

Absorption

[edit]

CoQ10 in the pure form is a crystalline powder insoluble in water. Absorption as a pharmacological substance follows the same process as that of lipids; the uptake mechanism appears to be similar to that of vitamin E, another lipid-soluble nutrient.[16] This process in the human body involves secretion into the small intestine of pancreatic enzymes and bile, which facilitates emulsification and micelle formation required for absorption of lipophilic substances.[44] Food intake (and the presence of lipids) stimulates bodily biliary excretion of bile acids and greatly enhances absorption of CoQ10. Exogenous CoQ10 is absorbed from the small intestine and is best absorbed if taken with a meal. Serum concentration of CoQ10 in fed condition is higher than in fasting conditions.[45][46]

Metabolism

[edit]

CoQ10 is metabolized in all tissues, with the metabolites phosphorylated in cells.[2] CoQ10 is reduced to ubiquinol during or after absorption in the small intestine.[2] It is absorbed by chylomicrons, and redistributed in the blood within lipoproteins.[2] Its elimination occurs via biliary and fecal excretion.[2]

Pharmacokinetics

[edit]

Some reports have been published on the pharmacokinetics of CoQ10. The plasma peak can be observed 6–8 hours after oral administration when taken as a pharmacological substance.[2] In some studies, a second plasma peak was observed approximately 24 hours after administration, probably due to enterohepatic recycling and redistribution from the liver to circulation.[44]

Deuterium-labeled crystalline CoQ10 was used to investigate pharmacokinetics in humans to determine an elimination half-time of 33 hours.[47]

Bioavailability

[edit]

In contrast to the intake of CoQ10 as a constituent of food, such as nuts or meat, from which CoQ10 is normally absorbed, there is a concern about CoQ10 bioavailability when it is taken as a dietary supplement.[48][49] Bioavailability of CoQ10 supplements may be reduced due to the lipophilic nature of its molecule and large molecular weight.[48]

Reduction of particle size

[edit]

Nanoparticles have been explored as a delivery system for various drugs, such as improving the oral bioavailability of drugs with poor absorption characteristics.[50] However, this has not proved successful with CoQ10, although reports have differed widely.[51][52] The use of aqueous suspension of finely powdered CoQ10 in pure water also reveals only a minor effect.[53]

Water-solubility

[edit]

Facilitating drug absorption by increasing its solubility in water is a common pharmaceutical strategy and also is successful for CoQ10. Various approaches have been developed to achieve this goal, with many of them producing significantly better results over oil-based soft gel capsules despite the many attempts to optimize their composition.[16] Examples of such approaches are use of the aqueous dispersion of solid CoQ10 with the polymer tyloxapol,[54] formulations based on various solubilising agents, such as hydrogenated lecithin,[55] and complexation with cyclodextrins; among the latter, the complex with β-cyclodextrin has been found to have highly increased bioavailability[56][57] and also is used in pharmaceutical and food industries for CoQ10-fortification.[16]

Adverse effects and precautions

[edit]

Generally, oral CoQ10 supplementation is well tolerated.[1] The most common side effects are gastrointestinal symptoms (nausea, vomiting, appetite suppression, and abdominal pain), rashes, and headaches.[58] Some adverse effects, largely gastrointestinal, are reported with intakes.[2] Doses of 100–300 mg per day may induce insomnia or elevate liver enzymes.[2] The observed safe level risk assessment method indicated that the evidence of safety is acceptable at intakes up to 1200 mg per day.[59]

Caution should be observed in the use of CoQ10 supplementation in people with bile duct obstruction and during pregnancy or breastfeeding.[2]

Potential drug interactions

[edit]

CoQ10 taken as a pharmacological substance has potential to inhibit the effects of theophylline as well as the anticoagulant warfarin; CoQ10 may interfere with warfarin's actions by interacting with cytochrome p450 enzymes thereby reducing the INR, a measure of blood clotting.[60] The structure of CoQ10 is similar to that of vitamin K, which competes with and counteracts warfarin's anticoagulation effects. CoQ10 is not recommended in people taking warfarin due to the increased risk of clotting.[58]

Dietary concentrations

[edit]

Detailed reviews on occurrence of CoQ10 and dietary intake were published in 2010.[61] Besides the endogenous synthesis within organisms, CoQ10 also is supplied by various foods.[1] CoQ10 concentrations in various foods are:[1]

CoQ10 levels in selected foods[61]
Food CoQ10 concentration (mg/kg)
Vegetable oils soybean oil 54–280
olive oil 40–160
grapeseed oil 64–73
sunflower oil 4–15
canola oil 64–73
Beef heart 113
liver 39–50
muscle 26–40
Pork heart 12–128
liver 23–54
muscle 14–45
Chicken breast 8–17
thigh 24–25
wing 11
Fish sardine 5–64
mackerel – red flesh 43–67
mackerel – white flesh 11–16
salmon 4–8
tuna 5
Nuts peanut 27
walnut 19
sesame seed 18–23
pistachio 20
hazelnut 17
almond 5–14
Vegetables parsley 8–26
broccoli 6–9
cauliflower 2–7
spinach up to 10
Chinese cabbage 2–5
Fruit avocado 10
blackcurrant 3
grape 6–7
strawberry 1
orange 1–2
grapefruit 1
apple 1
banana 1

Vegetable oils, meat, and fish are rich in CoQ10.[1] Dairy products are much poorer sources of CoQ10 than animal tissues. Among vegetables, broccoli and cauliflower are good sources of CoQ10.[1] Most fruits and berries are poor sources of CoQ10, except avocados, which have relatively high oil and CoQ10 content.[61]

Intake

[edit]

In the developed world, the estimated daily intake of CoQ10 has been determined at 3–6 mg per day, derived primarily from meat.[61]

South Koreans have an estimated average daily CoQ (Q9 + Q10) intake of 11.6 mg/d, derived primarily from kimchi.[62]

Effect of heat and processing

[edit]

Cooking by frying reduces CoQ10 content by 14–32%.[63]

History

[edit]

In 1950, a small amount of CoQ10 was isolated from the lining of a horse's gut, a compound initially called substance SA, but later deemed to be quinone found in many animal tissues.[64] In 1957, the same compound was isolated from mitochondrial membranes of beef heart, with research showing that it transported electrons within mitochondria. It was called Q-275 as a quinone.[64][65] The Q-275/substance SA was later renamed ubiquinone as it was a ubiquitous quinone found in all animal tissues.[64] In 1958, its full chemical structure was reported.[64][66] Ubiquinone was later called either mitoquinone or coenzyme Q due to its participation to the mitochondrial electron transport chain.[64] In 1966, a study reported that reduced CoQ6 was an effective antioxidant in cells.[67]

See also

[edit]
  • Idebenone – synthetic analog with reduced oxidant-generating properties
  • Mitoquinone mesylate – synthetic analog with improved mitochondrial permeability

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Coenzyme Q10

View on Grokipedia
from Grokipedia
Coenzyme Q10 (CoQ10), also known as ubiquinone, is a fat-soluble, vitamin-like molecule that is naturally present in every cellular membrane within the human body and plays crucial roles in mitochondrial energy production and antioxidant protection. It is synthesized endogenously in the mitochondria and obtained through dietary sources such as organ meats, fatty fish, and vegetables, with the highest concentrations found in energy-demanding organs like the heart, liver, kidneys, and pancreas. As an essential cofactor in the electron transport chain, CoQ10 facilitates the transfer of electrons to generate adenosine triphosphate (ATP), the primary energy currency of cells, supporting vital physiological processes. It also acts as a potent lipid-soluble antioxidant, neutralizing free radicals, reducing oxidative stress, and regenerating other antioxidants like vitamin E to protect cellular components such as proteins, lipids, and DNA from damage. Levels of CoQ10 naturally decline with age and in certain conditions, including cardiovascular diseases, neurodegenerative disorders, and statin use, prompting research into supplementation. CoQ10 is widely available as an over-the-counter in forms like ubiquinone (the oxidized form) and the reduced form , which support mitochondrial energy production and heart protection. Ubiquinol is generally more bioavailable than ubiquinone, especially in older adults, due to better absorption. As a result, effective doses of ubiquinol are often lower (typically 50-200 mg/day) compared to ubiquinone (100-300 mg/day or higher) to achieve similar CoQ10 levels. However, authoritative sources like the Mayo Clinic, WebMD, and NIH do not specify distinct dosage guidelines for each form and treat CoQ10 generally with typical doses of 100-300 mg/day (up to 1200 mg safe). No significant changes or new dosage differences were reported in 2025 or 2026; recommendations remain consistent with prior evidence. For general supplementation, typical doses range from 100 to 300 mg daily, with absorption improved by advanced formulations such as liposomal and nano-emulsified types that can enhance bioavailability by up to 3-4 times compared to standard forms, water-soluble forms that provide approximately 2.4-fold higher bioavailability compared to standard ubiquinone capsules, and by taking with meals containing fat due to its fat-soluble nature. Many experts recommend taking CoQ10 in the morning or at lunchtime to support daytime energy levels and to minimize potential sleep disturbances, as it may have mild energizing effects or cause insomnia in some individuals. Consistency in daily intake is considered more important than precise timing, and consultation with a healthcare professional is advised for personalized guidance. While not approved by the FDA for any medical condition, evidence from meta-analyses supports benefits for heart failure, including reductions in all-cause mortality and hospitalizations, and for migraines, with decreases in frequency, duration, and severity of attacks, particularly in older adults or those on statins with low CoQ10 levels; results suggest potential in reducing muscle damage associated with statins and protecting against heart damage from , and meta-analyses show that CoQ10 supplementation lowers blood pressure in hypertensive patients (systolic by up to 17 mmHg and diastolic by up to 10 mmHg, without significant side effects), improves glycemic control (reduces fasting glucose by ~5 mg/dL, fasting insulin by ~1.3 μIU/mL, HbA1c by 0.12%, and HOMA-IR by 0.69, with greatest benefits in diabetes patients at doses of 100-200 mg/day), and enhances endothelial function (increases flow-mediated dilation by ~1.45%, in a dose-dependent manner, with effects observed after 8 weeks); recent meta-analyses (2024–2025) indicate modest benefits for lowering systolic blood pressure in individuals with hypertension, with average reductions of around 4 mmHg and potentially more pronounced effects at lower doses, though effects on diastolic blood pressure are often smaller or inconsistent and it is not a standalone treatment but can complement lifestyle changes or medications; evidence is lacking for general prevention of conditions like Parkinson's disease, and further research is needed. Supplementation is generally safe up to 1,200 mg per day, with mild side effects like digestive upset or possible at higher doses, though it may interact with blood thinners like or affect blood sugar control in .

Chemical Properties

Molecular Structure

Coenzyme Q10, also known as ubiquinone-10, is a lipid-soluble molecule characterized by a 1,4-benzoquinone ring attached to a polyisoprenoid side chain consisting of ten isoprenoid units. Its molecular formula is C59H90O4C_{59}H_{90}O_4, reflecting the core quinone structure and the extended hydrophobic tail that facilitates its integration into cellular membranes. This architecture enables CoQ10 to participate in redox reactions within biological systems. CoQ10 exists in three redox states: the fully oxidized form (ubiquinone, CoQ10), the semiquinone radical intermediate (ubisemiquinone, CoQ10H•), and the fully reduced form (, CoQ10H2). These forms interconvert dynamically through one- and two-electron transfer processes, allowing CoQ10 to cycle between accepting electrons from complexes I and II and donating them to complex III in the mitochondrial . The reduced form predominates in tissues under normal physiological conditions, while the oxidized ubiquinone form is more prevalent during . The nomenclature "ubiquinone" derives from its ubiquitous presence in biological tissues and its chemical group, with the "10" indicating the ten isoprenyl subunits in the human variant. First isolated in 1957 by Frederick Crane and colleagues from beef heart mitochondria, its full —a substituted —was elucidated in 1958, leading to its recognition as coenzyme Q10. In humans and other vertebrates, CoQ10 features a 10-unit isoprenoid tail, distinguishing it from shorter-chain analogs such as coenzyme Q9 (CoQ9), which predominates in like mice and rats due to species-specific differences in the length of the polyprenyl tail. These structural variations influence and but do not alter the core functionality.

Physical and Chemical Characteristics

Coenzyme Q10 (CoQ10), also known as ubiquinone in its oxidized form, is a fat-soluble, lipophilic with very low , approximately 0.002 mg/mL at 25°C, which limits its dissolution in aqueous environments and influences its in pharmaceutical and nutritional applications. This hydrophobic nature stems from its long isoprenoid tail, making it highly soluble in lipids and organic solvents such as or oils, but practically insoluble in polar media without solubilizing agents. The of the ubiquinone/ couple is +0.045 V (at 7), enabling efficient two-electron transfer in biological systems while maintaining thermodynamic favorability for interactions with mitochondrial complexes. This potential, derived from the ring's ability to undergo reversible reduction, supports its function as a mobile carrier, with the structural isoprenyl chain contributing to its solubility. CoQ10 demonstrates sensitivity to environmental factors, degrading via oxidation when exposed to air, light, or elevated temperatures, which can convert the reduced form back to ubiquinone or lead to irreversible breakdown products. Such instability necessitates storage in dark, cool, and airtight conditions to preserve its bioactivity, particularly in supplemental formulations. Spectroscopically, the oxidized form of CoQ10 exhibits a characteristic UV absorption maximum at 275 nm, with a molar extinction coefficient of approximately 14,500 M⁻¹ cm⁻¹, allowing for reliable quantification in analytical assays such as HPLC. The reduced form shifts this absorption slightly to around 290 nm, reflecting changes in the upon reduction.

Biosynthesis

Biosynthetic Pathway

The biosynthesis of coenzyme Q10 (CoQ10), also known as ubiquinone, is a multi-step enzymatic process primarily occurring in the inner mitochondrial membrane of eukaryotic cells. It begins with the formation of the benzoquinone ring precursor, 4-hydroxybenzoate (4-HB), derived from the amino acids tyrosine or phenylalanine through a series of cytosolic reactions involving transamination, oxidative decarboxylation, and deamination. In prokaryotes, 4-HB is instead synthesized from chorismate via the shikimate pathway. The process then integrates an isoprenoid tail, produced from farnesyl pyrophosphate through the mevalonate pathway, which is elongated to a 10-unit polyprenyl chain by the enzyme COQ1 (deciprenyl diphosphate synthase, also known as PDSS1/PDSS2 in humans). This tail length is specific to humans and other vertebrates, contributing to the "10" in CoQ10. The first committed step in CoQ10 assembly is , catalyzed by COQ2 (polyprenyltransferase), which attaches the 10-unit polyprenyl diphosphate to the hydroxyl group of 4-HB, forming 3-decaprenyl-4-hydroxybenzoate (DDHB). Subsequent modifications to the ring occur within a multi-enzyme complex known as the Q-synthome, comprising COQ3 through COQ9, which facilitates efficient intermediate channeling. These modifications include at the C1 position (recently shown to involve COQ4 in eukaryotes; /UbiX in prokaryotes), hydroxylation at C5 (by COQ6, a monooxygenase) and C6 (by COQ7, a hydroxylase), O-methylation at C3 and C4 (by COQ3, using S-adenosylmethionine as the methyl donor), C-methylation at C2 (by COQ5), and C1-hydroxylation (enzyme unknown). Desaturation steps introduce double bonds to form the ring, completing the conversion to CoQ10. The exact order of some modifications remains partially unresolved, though studies in and human models indicate a general progression from DDHB to intermediates like 2-demethoxy-5-demethylubiquinol (DDMQH2) and ultimately to CoQ10. Additionally, RTN4IP1/OPA10 has been identified as a mitochondrial required for CoQ synthesis. In prokaryotes, the pathway differs notably in enzyme nomenclature (e.g., UbiA for , UbiG for ) and localization (cytoplasmic membrane rather than mitochondrial), with some steps potentially occurring in a different sequence, such as earlier . Additionally, prokaryotic can be anaerobic in certain , unlike the oxygen-dependent hydroxylations in eukaryotes. COQ4, COQ8 (a ), and COQ9 play structural roles in stabilizing the Q-synthome, ensuring coordinated . This pathway's conservation across domains of life underscores CoQ10's essential role, with disruptions in key enzymes linked to rare mitochondrial disorders.

Regulation of Synthesis

The biosynthesis of coenzyme Q10 (CoQ10) is subject to by nuclear receptors that respond to cellular metabolic demands, such as or the need for and isoprenoid intermediates. alpha (PPARα) upregulates key enzymes in the , including 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), thereby enhancing CoQ10 production in response to activators like di(2-ethylhexyl) phthalate. Similarly, sterol regulatory element-binding protein 2 (SREBP-2) activates transcription of genes, including HMGCR and synthase, during depletion, indirectly boosting CoQ10 synthesis as the pathway branches toward polyprenyl pyrophosphate formation. These regulators link CoQ10 production to broader and needs, ensuring coordinated responses to environmental stressors. Feedback mechanisms fine-tune CoQ10 synthesis to prevent excess accumulation, primarily through end-product inhibition and post-translational modifications of COQ enzymes. In eukaryotic systems, the final steps involving COQ7 (also known as ADCK3 in humans) are regulated by a phosphorylation-dephosphorylation cycle, where dephosphorylation by phosphatase Ptc7 activates the enzyme to convert demethoxyubiquinone to CoQ, while phosphorylated forms exhibit reduced activity, acting as a form of intermediate or product feedback. This modulation helps maintain optimal intermediate levels within the multi-enzyme COQ complex. Additionally, age-related decline in CoQ10 biosynthesis occurs due to reduced expression of COQ genes and impaired mevalonate pathway flux, with endogenous production dropping by approximately 50% from age 20 to 80, particularly affecting mitochondrial-rich tissues. Tissue-specific variations in CoQ10 synthesis reflect organ demands for energy production and antioxidant protection, with elevated levels in high-mitochondrial-density tissues like the heart and kidney. These organs exhibit higher expression of COQ biosynthetic genes to support robust electron transport chain activity, resulting in CoQ10 concentrations up to 4-5 times greater than in low-energy tissues such as the spleen. Genetic factors play a critical role in CoQ10 synthesis regulation, where mutations in COQ genes disrupt the pathway and lead to primary deficiencies. For example, pathogenic variants in COQ2 impair the initial prenylation step, while COQ4 mutations destabilize the COQ enzyme complex, both resulting in severely reduced CoQ10 levels and mitochondrial dysfunction across affected tissues. Over 150 such mutations have been identified across at least 10 COQ genes, highlighting their essential role in maintaining synthetic homeostasis.

Biological Functions

Role in Mitochondrial Electron Transport

Coenzyme Q10 (CoQ10), also known as ubiquinone, functions as a mobile electron carrier embedded within the of the , facilitating the transfer of s between respiratory complexes during . It exists in oxidized (ubiquinone), semiquinone (ubisemiquinone), and reduced () forms, allowing it to shuttle reducing equivalents derived from nutrient oxidation. This mobility is essential for efficient electron flow, as CoQ10 diffuses freely in the to interact with the flavin sites of Complexes I and II. CoQ10 accepts electrons primarily from Complex I (NADH:ubiquinone oxidoreductase), which transfers two electrons from NADH, and from Complex II (succinate:ubiquinone oxidoreductase), which transfers two electrons from FADH₂ produced in the tricarboxylic acid cycle. These electrons reduce CoQ10 to in a two-step process, first forming the semiquinone intermediate and then fully reducing it. The then diffuses to Complex III (cytochrome bc1 complex), where it donates electrons via the Q-cycle mechanism, a process first elucidated in the 1970s. The Q-cycle enables the transfer of electrons from ubiquinol to cytochrome c while amplifying proton translocation across the inner membrane. In the first half of the cycle, ubiquinol binds to the Qo site of Complex III, releasing two protons to the intermembrane space and donating one electron to the Rieske iron-sulfur protein (leading to cytochrome c reduction) and the other to a semiquinone intermediate at the Qi site. A second ubiquinol molecule then completes the cycle by reducing the semiquinone to ubiquinone, taking up two protons from the matrix, resulting in a net translocation of four protons per two electrons transferred. This proton gradient contributes to the proton motive force that drives ATP synthesis via Complex V (ATP synthase), supporting the production of approximately 30-32 ATP molecules per glucose molecule oxidized through complete respiration. Depletion of CoQ10 impairs this electron transport, leading to reduced respiratory chain efficiency and diminished ATP production, as observed in primary CoQ10 deficiency syndromes where mitochondrial respiration rates drop significantly. Such deficiencies disrupt the Q-cycle, causing electron leakage and a compensatory increase in reactive oxygen species (ROS) generation from partially reduced oxygen species at Complexes I and III. This oxidative stress exacerbates mitochondrial dysfunction, highlighting CoQ10's indispensable role in maintaining bioenergetic homeostasis. The ubiquinol form of CoQ10 particularly improves mitochondrial function in nerves by enhancing electron transport chain activity and ATP production, while supporting energy metabolism in tissues such as the liver and cochlea. Studies indicate that supplementation with 200–400 mg/day of ubiquinol can increase brain mitochondrial CoQ10 levels and reduce oxidative damage in neuronal tissues.

Antioxidant and Other Roles

Coenzyme Q10 (CoQ10), particularly in its reduced form, serves as a potent lipid-soluble that scavenges free radicals and protects cellular membranes from oxidative damage. donates electrons to neutralize (ROS), thereby preventing the propagation of chains in biological membranes and lipoproteins. This radical scavenging activity is especially critical in mitochondria, where CoQ10's role in electron transport can generate ROS as a byproduct, allowing it to mitigate directly at the site of production. Additionally, CoQ10 regenerates other , such as (), by reducing its oxidized form back to the active state, enhancing the overall network in cells. It also reduces lipid peroxides, such as (MDA), in various tissues, thereby stabilizing membrane integrity and preventing cellular dysfunction. Beyond direct scavenging, CoQ10 modulates to bolster antioxidant defenses, notably by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Upon activation, Nrf2 translocates to the nucleus and induces the expression of antioxidant response element (ARE)-driven genes, including those encoding superoxide dismutase (SOD), catalase (CAT), and oxygenase-1 (HO-1), which collectively enhance cellular resistance to . This mechanism has been observed in models of and , where CoQ10 supplementation upregulates Nrf2 signaling to counteract ROS-induced damage. CoQ10 also influences broader gene regulation, such as modulating expression (e.g., miR-146a) and genes involved in , further supporting adaptive responses to oxidative challenges. In addition to its core antioxidant functions, CoQ10 contributes to cardiovascular protection by improving endothelial function through enhanced nitric oxide (NO) bioavailability and reduced oxidative stress on vascular cells. This preservation of NO helps maintain vasodilation and vascular health, mitigating endothelial dysfunction associated with high oxidative environments. CoQ10 also supports sperm motility in reproductive cells by counteracting ROS-induced damage to sperm membranes and enhancing antioxidant enzyme activities like SOD and CAT, leading to improved progressive motility parameters. Regarding tissue distribution, CoQ10 concentrations are highest in organs with elevated oxygen consumption and metabolic demands, such as the heart (up to 114 μg/g tissue), kidney, liver, and skeletal muscle, reflecting its strategic localization to protect energy-intensive tissues from oxidative insults. As an antioxidant supplement, CoQ10 in ubiquinone or ubiquinol capsule forms supports mitochondrial energy production and provides heart protection by mitigating oxidative stress and enhancing electron transport efficiency. Evidence from meta-analyses indicates benefits for heart failure, including reduced all-cause mortality, fewer hospitalizations, and improved left ventricular ejection fraction, particularly in patients with chronic heart failure. Supplementation also shows promise in reducing the frequency, duration, and severity of migraine attacks. These benefits are especially relevant for older adults experiencing age-related declines in CoQ10 levels and individuals on statin therapy, where supplementation can alleviate statin-associated muscle symptoms and restore depleted antioxidant capacity. However, drawbacks include poor and variable absorption, necessitating lipid-soluble formulations and co-administration with fatty meals for optimal bioavailability, as well as a lack of strong evidence supporting its use for general disease prevention in healthy populations.

Sources and Intake

Endogenous Production

Coenzyme Q10 (CoQ10) is synthesized endogenously in cells, primarily within the mitochondria, to meet the majority of the body's daily requirements. The total body pool of CoQ10 is approximately 2 g in adults, with a turnover rate of about 500 mg per day, of which dietary contributes only a minor fraction (typically 3–5 mg). This endogenous output peaks during young adulthood and declines progressively thereafter, with myocardial levels reduced to roughly 50% of peak levels by age 80. Within cells, CoQ10 is predominantly localized in the , where it supports electron transport, but it is also distributed to other compartments, including plasma membranes, lysosomes, and Golgi apparatus, comprising up to 40–50% of total cellular content in mitochondrial fractions in various tissues. Physical exercise increases the demand for CoQ10 in muscle tissues, potentially enhancing uptake from plasma to meet heightened needs. In contrast, certain metabolic conditions may alter production rates, though the precise mechanisms linking overall output to physiological stressors remain under investigation.

Dietary Sources and Concentrations

Coenzyme Q10 is primarily obtained from animal-derived foods, which serve as the richest dietary sources. Organ meats, in particular, contain high concentrations, with beef heart providing approximately 11.3 mg per 100 g and chicken liver around 11.6–13.2 mg per 100 g. Fatty also contribute notably, such as sardines at up to 6.4 mg per 100 g and at about 6.8 mg per 100 g. These levels reflect the compound's role in mitochondrial function within metabolically active tissues like hearts and livers. In contrast, plant-based sources offer lower amounts of coenzyme Q10, making them less significant contributors to intake. Vegetables like contain 0.4–1.0 mg per 100 g, while provides 0.6–0.9 mg per 100 g. Nuts, seeds, and vegetable oils (e.g., or canola oil) can supply modest quantities, typically 1–3 mg per 100 g, but fruits, berries, and most other plant foods have trace levels below 0.5 mg per 100 g. The average daily dietary intake of coenzyme Q10 in Western diets ranges from 3 to 6 mg, predominantly from , , and , which account for 50–80% of total consumption. This intake occurs mostly in the oxidized form (ubiquinone), though animal sources contain a higher proportion of the reduced form (), estimated at around 50% overall in the diet. Food processing can diminish coenzyme Q10 content and bioavailability. Heat-based methods like frying lead to 14–32% loss, while boiling causes minimal degradation. Additionally, oxidation during storage, particularly in oils and processed products, further reduces available levels by promoting conversion to inactive forms.

Deficiency

Causes of Deficiency

Coenzyme Q10 (CoQ10) deficiency can be classified as primary or secondary, with primary forms arising directly from genetic disruptions in the CoQ10 biosynthetic pathway. Primary CoQ10 deficiency is a rare autosomal recessive disorder caused by biallelic pathogenic variants in genes encoding proteins essential for CoQ10 synthesis, including PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A (also known as ADCK3), COQ8B (also known as ADCK4), and COQ9. These mutations impair the production of CoQ10, leading to multisystem involvement often manifesting in infancy or early childhood; for example, mutations in COQ2 are associated with a severe encephalopathy characterized by early-onset seizures and developmental delay. The prevalence of primary CoQ10 deficiency is estimated at approximately 1 in 100,000 individuals worldwide (as of 2023), with some studies suggesting around 120,000 affected globally based on genetic variant frequencies. Secondary CoQ10 deficiency occurs due to factors that indirectly impair CoQ10 synthesis, transport, or utilization, without direct genetic defects in the biosynthetic genes. A prominent cause is the use of medications, which inhibit in the mevalonate pathway, thereby reducing the availability of needed for the polyisoprenoid tail of CoQ10; this can result in plasma CoQ10 reductions of up to 40% within weeks of treatment initiation. Similarly, beta-blockers such as have been shown to decrease myocardial CoQ10 levels by interfering with cellular uptake and utilization, contributing to and reduced cardiac efficiency in affected patients. Aging represents a major non-pharmacological cause of secondary deficiency, with CoQ10 levels in tissues declining progressively; myocardial CoQ10 concentrations, for instance, peak around age 20 and decrease by approximately 50% by age 80, exacerbating and mitochondrial dysfunction. Mitochondrial diseases, such as those involving defects (e.g., ), often lead to secondary CoQ10 deficiency by disrupting mitochondrial integrity and increasing oxidative demands that outpace endogenous production. Intense physical exercise can transiently lower CoQ10 levels due to heightened utilization and in muscle tissues, particularly in untrained individuals or during prolonged activities. Patients with chronic often have reduced CoQ10 levels, with average myocardial concentrations about 33% lower than in healthy individuals and correlating with disease severity, independent of primary genetic causes. Additionally, acute infectious diseases such as influenza can cause secondary CoQ10 deficiency through depletion associated with oxidative stress. Observational studies have demonstrated significantly lower serum CoQ10 levels in patients with acute influenza compared to healthy controls (e.g., 0.53 μg/mL vs. 0.98 μg/mL, p<0.001), with greater reductions in severe cases like H1N1 versus seasonal influenza (752.2 ± 163 ng/mL vs. 1022 ± 199 ng/mL, p=0.003). These reductions show weak correlations with inflammatory markers (e.g., r= -0.28 for CRP, p=0.047) and disease severity, indicating that the depletion is likely due to heightened oxidative stress during infection.

Symptoms and Diagnosis

Coenzyme Q10 (CoQ10) deficiency manifests through a of symptoms, primarily affecting production in mitochondria, with presentations varying by age of onset and severity. In milder, secondary forms often linked to aging or chronic diseases, common symptoms include fatigue, , and due to impaired . In primary genetic deficiencies, which are rarer, symptoms can be more severe and multisystemic; infantile-onset cases may present with encephalomyopathy characterized by seizures, , and developmental delay, while childhood-onset forms often involve , , and . Severe manifestations in primary deficiencies can extend to with , renal tubular dysfunction leading to failure, and optic , typically appearing in infancy or . These symptoms overlap with other mitochondrial disorders, complicating initial clinical assessment and necessitating . Diagnosis of CoQ10 deficiency relies on biochemical rather than symptoms alone, as no single clinical feature is . The gold standard method involves measuring CoQ10 levels in biopsy via (HPLC), where levels below 20-30% of age-matched controls indicate deficiency; this approach also assesses mitochondrial respiratory chain activity through enzyme assays showing reduced complexes I-III function. Plasma CoQ10 levels, measured by HPLC with electrochemical or UV detection, provide a less invasive screening tool, with concentrations below 0.5 µg/mL suggestive of deficiency, though normal ranges vary widely (typically 0.5-1.5 µg/mL) due to factors like age, diet, and tissue distribution, limiting its diagnostic specificity. For primary deficiencies, via next-generation sequencing of CoQ10 genes (e.g., COQ2, PDSS2) confirms once biochemical evidence is established. Advanced assessments may include the (reduced) to ubiquinone (oxidized) ratio in plasma or muscle via HPLC to evaluate status, though no standardized exists owing to inter-individual variability.

Pharmacology

Absorption and Bioavailability

Coenzyme Q10 (CoQ10), primarily in its oxidized form ubiquinone, is absorbed in the through a lipid-like process involving emulsification by salts and pancreatic enzymes, which facilitate its incorporation into mixed micelles for presentation to the . Once at the , CoQ10 is taken up by enterocytes via due to its lipophilic nature, without reliance on energy-dependent transporters. Following absorption, it is reduced to within the enterocytes and packaged into chylomicrons for lymphatic transport to the bloodstream; upon reaching the liver, it is redistributed into very low-density lipoproteins (VLDL), which mature into low-density lipoproteins (LDL) for systemic delivery. The of standard ubiquinone CoQ10 from oral supplements or diet is low, typically ranging from 2% to 3%, owing to its poor water and high molecular weight, which limit dissolution and in the . Absorption efficiency is notably enhanced when CoQ10 is consumed with fatty meals, as dietary promote formation and increase uptake by 2- to 3-fold compared to conditions. As a fat-soluble substance, CoQ10 is best taken with meals containing fat to maximize absorption. Although there is no strict universal optimal time of day, many experts recommend morning or lunchtime intake to support daytime energy levels and minimize potential sleep interference, as higher doses (100 mg/day or more) have been associated with mild insomnia in some individuals due to possible energizing effects. Consistency of intake and pairing with fatty foods are the most critical factors for effective absorption; consultation with a healthcare provider is advised for personalized recommendations. Oil-based soft capsules are considered optimal for both ubiquinone and ubiquinol forms when taken with fatty meals, further improving absorption due to the lipophilic nature of CoQ10. Several formulation strategies mitigate these limitations by improving and stability. Reducing through nano-emulsification disperses CoQ10 into finer droplets, enhancing dissolution rates and by 3- to 4-fold relative to crystalline forms, as demonstrated in pharmacokinetic studies measuring increased area under the curve (AUC) and maximum plasma concentration (C_max). Liposomal or nano-emulsified formulations can raise absorption 3-5 times by protecting CoQ10 from stomach acid and improving stability in the gastrointestinal tract. Similarly, water-soluble forms, such as solubilized or products like Q10Vital, exhibit up to 2.4-fold greater than standard ubiquinone capsules, particularly in older adults, due to better stability in aqueous environments and more efficient reduction during absorption. Some studies indicate that ubiquinol generally has higher absorption and bioavailability than ubiquinone, especially in older adults due to reduced conversion ability, with up to 3-4 times better absorption than ubiquinone; however, results vary depending on formulation and individual factors. This enhanced bioavailability is particularly important in older adults, where absorption efficiency becomes more critical as natural CoQ10 production drops significantly with age—declining by about 50% by age 80 in tissues like the heart—and uptake can decline, making dietary supplementation especially relevant. Recent advances in delivery systems, including liposomal encapsulation, further optimize absorption by embedding CoQ10 within bilayers that mimic cellular membranes, facilitating direct fusion with enterocytes. A 2025 clinical study reported approximately 23% higher AUC and 31% higher C_max with liposomal CoQ10 compared to conventional ubiquinone, indicating modest improvements in for populations with compromised absorption.

Metabolism and Pharmacokinetics

Coenzyme Q10 (CoQ10), primarily in its reduced form as ubiquinol, is widely distributed throughout the body following absorption, with the highest concentrations found in tissues with high energy demands such as the heart, liver, kidneys, and skeletal muscles. The apparent volume of distribution is large, approximately 20.4 L/kg after intravenous administration, reflecting extensive tissue penetration and incorporation into cellular membranes and mitochondria. Its elimination half-life in plasma is about 33 hours, allowing for sustained presence in tissues after dosing. In metabolism, absorbed CoQ10 undergoes reduction to its active ubiquinol form, mediated by enzymes such as DT-diaphorase (NQO1), which facilitates two-electron transfer to maintain the antioxidant pool and prevent semiquinone radical formation. Catabolism involves shortening of the isoprenoid side chain, likely through oxidative processes including beta-oxidation-like mechanisms, producing polar metabolites with shortened chains that are phosphorylated for excretion. These metabolites are primarily eliminated via biliary and fecal routes, with a minor fraction appearing in urine. Pharmacokinetically, oral CoQ10 reaches peak plasma concentrations 6 to 8 hours after ingestion, depending on formulation solubility. Steady-state plasma levels are typically achieved after 1 to 2 weeks of daily supplementation, with clearance influenced by dose and bioavailability enhancements. Tissue accumulation follows a gradient, with the heart exhibiting the highest uptake compared to liver and plasma levels. Plasma CoQ10 concentrations serve as a reliable for monitoring supplementation compliance, as levels correlate directly with intake and reflect overall body status.

Supplementation and Clinical Use

Forms and Therapeutic Applications

Coenzyme Q10 (CoQ10) is available in two primary supplemental forms: ubiquinone, the oxidized form, and , the reduced form. Standard CoQ10 supplements typically contain the oxidized form, ubiquinone, unless specifically labeled as the reduced form, ubiquinol. demonstrates superior compared to ubiquinone, particularly in older adults, due to its enhanced absorption and reduced need for metabolic conversion in the body. Some studies suggest that ubiquinol is absorbed 3 to 4 times better than ubiquinone, especially for older people or those with reduced conversion ability, potentially providing effects comparable to higher doses of ubiquinone, such as 100 mg of ubiquinol equating to 200-400 mg of ubiquinone; however, results are mixed and depend on formulation factors. This difference arises because is more water-soluble and readily utilized by cells, leading to higher plasma levels following supplementation. For detailed information on absorption and bioavailability, see the Pharmacology section. Due to its superior bioavailability, particularly in older adults, effective doses of ubiquinol are often lower, typically 50–200 mg/day, compared to ubiquinone doses of 100–300 mg/day or higher to achieve similar CoQ10 plasma levels. However, authoritative sources such as the Mayo Clinic and WebMD do not provide distinct dosage guidelines for ubiquinol and ubiquinone, instead offering general recommendations for CoQ10 of 100–300 mg/day (with higher doses up to 1200 mg considered safe). As a lipid-soluble antioxidant supplement in ubiquinone or ubiquinol capsule form, CoQ10 supports mitochondrial energy production and heart protection, with particular benefits for older adults or those on statins experiencing low CoQ10 levels. The ubiquinol form has demonstrated benefits in improving mitochondrial function in nerve tissues, supporting energy production and reducing oxidative stress in neurological applications. Doses of 200-400 mg/day have shown promise in conditions such as Friedreich's ataxia and Parkinson's disease. For general health supplementation, particularly with the ubiquinone form, a dosage of 100-200 mg per day is commonly recommended, with typical doses ranging from 100 to 300 mg per day, often taken with meals containing fats to optimize absorption due to its lipid-soluble nature. However, there is a lack of strong evidence supporting CoQ10 supplementation for the general prevention of diseases. In therapeutic contexts, such as for specific diseases, higher doses up to 1200 mg per day are commonly used, with some clinical protocols extending to 3000 mg under medical supervision. In cardiovascular applications, CoQ10 supplementation has shown efficacy in lowering blood pressure in people with hypertension. Meta-analyses of randomized controlled trials indicate reductions in systolic blood pressure (SBP) of around 3-4 mmHg (e.g., −3.44 mmHg overall and −3.86 mmHg in patients with type 2 diabetes), particularly at doses below 200 mg per day and with interventions longer than 8 weeks, while earlier meta-analyses suggested potential reductions of up to 17 mmHg in SBP and 10 mmHg in DBP without significant side effects. Effects on diastolic blood pressure (DBP) are smaller or inconsistent, with one analysis showing a reduction of −2.70 mmHg in type 2 diabetes patients. These benefits may stem from improved endothelial function (with meta-analyses showing increases in flow-mediated dilation of approximately 1.45% in a dose-dependent manner, effects observed after 8 weeks), reduced oxidative stress, and better vascular health, making CoQ10 a promising adjunctive therapy to complement lifestyle changes or medications, though not a standalone treatment. A 2024 of 33 randomized controlled trials also found that CoQ10 supplementation as an adjunct therapy in patients reduced all-cause mortality (RR 0.64), hospitalization for heart failure (RR 0.50), and improved left ventricular , with no increase in adverse events. There is limited reliable evidence supporting a specific synergistic effect between coenzyme Q10 and magnesium on cardiovascular health, heart failure, or blood pressure regulation. A single case study from 2006 reported symptom improvement in a heart failure patient treated with a combination of CoQ10, hawthorn, and magnesium. While CoQ10 has evidence from meta-analyses for reducing heart failure symptoms and mortality risk as well as modestly lowering blood pressure, and magnesium supports blood pressure regulation particularly in deficient individuals, no large-scale randomized controlled trials confirm enhanced combined effects beyond their individual benefits. Meta-analyses of randomized controlled trials also demonstrate that CoQ10 supplementation improves glycemic control in patients with diabetes, reducing fasting glucose by approximately 5 mg/dL, fasting insulin by approximately 1.3 μIU/mL, HbA1c by 0.12%, and HOMA-IR by 0.69, with greatest benefits at doses of 100-200 mg/day. For mitochondrial disorders, high-dose CoQ10 (up to 30 mg/kg/day in children or 1.2-3 g/day in adults) is a therapy for primary CoQ10 deficiencies, leading to improvements in clinical symptoms, muscle strength, and biochemical markers like lactate levels. CoQ10 has also demonstrated benefits in migraine prophylaxis, with meta-analyses showing reductions in attack frequency, duration, and severity, attributed to its antioxidant and anti-inflammatory properties. Emerging applications include enhancement in both women and men. Both ubiquinol and ubiquinone forms of CoQ10 support fertility via antioxidant effects and mitochondrial support, with potential to improve egg quality in women (including oocyte rejuvenation and embryo quality in assisted reproduction) and sperm parameters in men (such as motility, morphology, and concentration). A 2025 review highlights CoQ10's potential to rejuvenate aging oocytes by restoring mitochondrial function and improving quality in women undergoing assisted . Systematic reviews indicate benefits for sperm quality in men with infertility. Ubiquinol generally has better bioavailability than ubiquinone, particularly in older adults where conversion capacity declines with age, leading some experts to recommend ubiquinol for fertility applications. However, most clinical studies demonstrating fertility benefits have used ubiquinone, and there is no strong evidence that ubiquinol produces significantly better fertility outcomes. Ubiquinol also tends to be more expensive and less stable. In cognitive health, a 2023 systematic review of studies on CoQ10 in and reported mixed results, with some trials showing improvements in cognitive function but overall evidence being inconclusive. Preliminary studies have investigated Coenzyme Q10 supplementation, often in combination with L-carnitine, for benign prostatic hyperplasia (BPH), with one randomized controlled trial demonstrating significant reductions in prostate volume and improvements in erectile function, but no significant effects on lower urinary tract symptoms, quality of life, or PSA levels. Observational data suggest a potential association between moderate plasma CoQ10 levels and reduced prostate cancer risk, though findings are weak and not statistically significant. Additionally, a randomized trial has shown that CoQ10 supplementation can significantly reduce serum PSA levels in healthy men. No specific evidence supports the use of CoQ10 for prostatitis. The evidence for these applications remains limited and preliminary, characterized by small sample sizes and inconsistent results, necessitating further research to establish clinical utility. Regarding statin-induced , CoQ10 supplementation provides relief in mild-to-moderate cases, with multiple randomized trials demonstrating reduced muscle pain and improved symptoms at doses of 100-200 mg daily, though some meta-analyses report inconsistent overall benefits. For , clinical trials yield mixed results; while early-phase studies suggested potential slowing of disease progression at high doses (1200-2400 mg/day), larger randomized trials found no significant improvement in Unified Parkinson's Disease Rating Scale scores.

Adverse Effects and Interactions

Coenzyme Q10 supplementation is generally well-tolerated, with mild gastrointestinal disturbances such as , , and upper reported as the most common adverse effects, occurring infrequently at doses up to 300 mg daily. Other rare side effects include , particularly at doses exceeding 100 mg per day, and skin rash, though these are uncommon and typically resolve upon discontinuation. Coenzyme Q10 holds (GRAS) status for use in dietary supplements, with no evidence of serious observed even at high doses up to 1,200 mg daily. Interactions with medications warrant caution. Coenzyme Q10 may enhance the hypotensive effects of antihypertensive drugs, potentially leading to additive lowering, so monitoring is advised in patients on such therapies. It can also reduce the anticoagulant efficacy of by interfering with vitamin K-dependent clotting factors, necessitating regular monitoring of international normalized ratio (INR) levels to adjust dosing as needed. Additionally, coenzyme Q10 supplementation may improve tolerance to statins by mitigating statin-associated muscle symptoms, such as , which arise partly from statin-induced coenzyme Q10 depletion. Precautions are recommended for specific populations due to limited data. In pregnancy, evidence on safety is insufficient, and supplementation should be avoided or used only under medical supervision to prevent potential risks, despite no reported adverse fetal outcomes in available studies. Overdose does not appear to cause toxicity, as clinical trials have shown no serious adverse events at doses up to 2,400 mg daily. Long-term use, including in trials lasting up to two years, demonstrates no evidence of harm, supporting its safety for extended supplementation when monitored appropriately. Regarding the combination of coenzyme Q10 with acetyl-L-carnitine in healthy adults, available data indicate reassuring long-term safety profiles for both components, with no evidence of cumulative toxicity observed. While ultra-long-term studies exceeding 10 years specifically for this combination are limited, individual components have shown no red flags in trials lasting up to several years.

Research Directions

Historical Development

Coenzyme Q10, also known as ubiquinone, was first isolated in 1957 by Frederick L. Crane and colleagues from beef heart mitochondria at the University of Wisconsin-Madison. The compound was named ubiquinone to reflect its widespread occurrence across biological tissues and organisms. This discovery arose from studies on mitochondrial electron transport chains, highlighting CoQ10's role in cellular energy production. In 1958, Karl August Folkers and his team at Merck & Co. determined the precise chemical structure of ubiquinone, confirming it as a quinone derivative with a polyisoprenoid side chain. Throughout the 1960s, Folkers' research advanced understanding of CoQ10's biosynthesis pathway, demonstrating its endogenous production from tyrosine and revealing its essential function in the mitochondrial respiratory chain. By the 1970s, Folkers and collaborators, including Gian Paolo Littarru, linked reduced CoQ10 levels to human heart disease through tissue biopsies of cardiac patients, marking the first documentation of CoQ10 deficiency in a clinical context. A significant milestone occurred in 1978 when Peter Mitchell was awarded the for the chemiosmotic theory, which elucidated CoQ10's critical role in proton translocation during . The first primary genetic deficiency of CoQ10 was reported in 1989, involving siblings with and renal dysfunction due to impaired biosynthesis. In the 1990s, investigations revealed that medications, widely used for management, inhibit the , thereby depleting CoQ10 levels and contributing to -associated . CoQ10 supplements became commercially available in the 1970s, following methods developed in during the 1960s, which enabled large-scale production. CoQ10 supplements became commercially available in the United States as dietary supplements, with manufacturers self-affirming GRAS status to support their use as nutritional aids.

Recent Studies and Future Prospects

A 2024 meta-analysis of 28 randomized controlled trials involving 830 participants demonstrated that coenzyme Q10 (CoQ10) supplementation significantly reduces biomarkers of exercise-induced muscle damage (EIMD), including creatine kinase (CK) by a weighted mean difference (WMD) of -50.64 IU/L and lactate dehydrogenase (LDH) by -52.10 IU/L, with dose-dependent effects observed for each 100 mg/day increase. In fertility research, a 2025 review highlighted CoQ10's role in oocyte rejuvenation, showing that supplementation during oocyte growth phases significantly improves mitochondrial function, reduces oxidative stress, and enhances embryo quality in aging oocytes, potentially benefiting women with diminished ovarian reserve. Recent investigations into anti-aging have explored systemic effects, with a 2025 review indicating that oral CoQ10 supplementation supports overall capacity, potentially mitigating age-related skin changes through improved cellular energy production and reduced , though direct dermatological outcomes require further validation. Addressing research gaps, a 2025 meta-review of 14 studies on found improved cognitive function in 12 trials following CoQ10 supplementation, attributed to enhanced mitochondrial and reduced in neurodegenerative contexts. Conversely, a 2025 trends analysis of supplement use reported no significant association between CoQ10 intake and cancer risk, suggesting neutral effects on oncogenesis despite its properties. Looking ahead, targeted delivery systems like liposomal formulations have shown promise, with a 2025 randomized reporting 31.3% higher peak plasma concentrations and 22.6% greater area under the curve for liposomal CoQ10 compared to standard forms, enhancing for therapeutic applications. For primary CoQ10 deficiencies, emerging therapies aim to restore pathways, as a 2025 study demonstrated that combined treatments targeting multiple organs improved metabolic functions in deficient models, paving the way for gene-based interventions. Ongoing clinical trials are evaluating CoQ10 in , with a phase 2 crossover study finding no significant improvement in post-COVID but potential benefits for via high-dose supplementation. In neurodegeneration, prospective research highlights potential in mitigating mitochondrial dysfunction, supported by evidence of in aging models. Reviews have hypothesized anti-inflammatory benefits and mitochondrial support from CoQ10 supplementation in viral infections such as influenza, potentially mitigating oxidative stress and inflammation associated with acute infections. However, no direct clinical trials have demonstrated its efficacy in preventing or treating influenza. Key challenges include the need for standardized assays to measure CoQ10 levels accurately across tissues, as variability in detection methods hinders comparative studies, and long-term randomized controlled trials to substantiate anti-aging claims beyond short-term biomarkers.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK531491/
  2. https://www.nccih.nih.gov/health/coenzyme-q10
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3178961/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4068099/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7146408/
  6. https://www.health.com/best-time-to-take-coq10-11844522
  7. https://pubmed.ncbi.nlm.nih.gov/17287847/
  8. https://pubmed.ncbi.nlm.nih.gov/35958521/
  9. https://pubmed.ncbi.nlm.nih.gov/38630421/
  10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092430/
  11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11939526/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC11441719/
  13. https://pubmed.ncbi.nlm.nih.gov/40495903/
  14. https://onlinelibrary.wiley.com/doi/10.1002/hsr2.70452/
  15. https://pubchem.ncbi.nlm.nih.gov/compound/Coenzyme-Q10
  16. https://www.sciencedirect.com/topics/chemistry/coenzyme-q10
  17. https://hmdb.ca/metabolites/HMDB0001072
  18. https://lpi.oregonstate.edu/mic/dietary-factors/coenzyme-Q10
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC11203502/
  20. https://www.mdpi.com/2076-3921/9/5/386
  21. https://www.cancer.gov/about-cancer/treatment/cam/hp/coenzyme-q10-pdq
  22. https://journal.houstonmethodist.org/articles/10.14797/mdcj-15-3-185
  23. https://www.medlink.com/articles/coenzyme-q10
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC8826242/
  25. https://www.mdpi.com/2076-3921/10/4/520
  26. https://www.sciencedirect.com/science/article/pii/S1360138525002353
  27. https://www.nature.com/articles/s41538-025-00465-0
  28. https://go.drugbank.com/salts/DBSALT001598
  29. https://www.chegg.com/homework-help/questions-and-answers/standard-reduction-potential-e-redox-pair-fad-fadh2-0219v-redox-pair-ubiquinone-ubiquinol--q86531830
  30. https://www.sciencedirect.com/science/article/pii/S0005272813001862
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC7997171/
  32. https://www.sciencedirect.com/science/article/abs/pii/S0144861710005461
  33. https://www.sciencedirect.com/science/article/pii/S0021925824018027
  34. https://akjournals.com/view/journals/1326/aop/article-10.1556-1326.2025.01277/article-10.1556-1326.2025.01277.xml
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC10106368/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC5731490/
  37. https://www.mdpi.com/2076-3921/12/7/1469
  38. https://doi.org/10.1016/j.molcel.2024.01.003
  39. https://doi.org/10.1038/s41589-023-01452-w
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4112530/
  41. https://www.nature.com/articles/s41392-022-01125-5
  42. https://www.sciencedirect.com/science/article/pii/S0047637421000932
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC6131403/
  44. https://www.sciencedirect.com/science/article/pii/S0002929707623659
  45. https://www.mdpi.com/2076-3921/12/8/1652
  46. https://doi.org/10.3390/antiox10040520
  47. https://doi.org/10.1016/j.bbabio.2016.03.010
  48. https://doi.org/10.1016/0014-5793(75)80359-0
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC9054193/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC4025630/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC7278738/
  52. https://www.ocl-journal.org/articles/ocl/full_html/2011/02/ocl2011182p76/ocl2011182p76.html
  53. https://journals.lww.com/rips/fulltext/2019/14060/possible_antioxidant_mechanism_of_coenzyme_q10_in.6.aspx
  54. https://onlinelibrary.wiley.com/doi/10.1155/2024/2247748
  55. https://pubmed.ncbi.nlm.nih.gov/21388622/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC8226917/
  57. https://www.mdpi.com/1422-0067/21/18/6695
  58. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515203/
  59. https://pubmed.ncbi.nlm.nih.gov/27670440/
  60. https://www.cureus.com/articles/280147-coenzyme-q10-supplementation-in-statin-associated-muscle-symptoms-a-systematic-review-and-meta-analysis#!/
  61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495827/
  62. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278738/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC6627360/
  64. https://www.bjd-abcd.com/index.php/bjd/article/view/251/441
  65. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2018.00044/full
  66. https://jissn.biomedcentral.com/articles/10.1186/1550-2783-10-24
  67. https://www.sciencedirect.com/science/article/abs/pii/S0308814613015872
  68. https://www.ncbi.nlm.nih.gov/books/NBK410087/
  69. https://medlineplus.gov/genetics/condition/primary-coenzyme-q10-deficiency/
  70. https://jamanetwork.com/journals/jamaneurology/fullarticle/786017
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC4112525/
  72. https://openheart.bmj.com/content/9/1/e001927
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC9495827/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC8092430/
  75. https://pubmed.ncbi.nlm.nih.gov/30156030/
  76. https://pubmed.ncbi.nlm.nih.gov/22913153/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC7555759/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC4112523/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC3222743/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC5372996/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC8773271/
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC4112526/
  83. https://onlinelibrary.wiley.com/doi/10.1002/ardp.202300676
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC10376127/
  85. https://www.tandfonline.com/doi/full/10.2147/NDS.S112119
  86. https://clinicaltrials.gov/study/NCT40
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC7697799/
  88. https://pubmed.ncbi.nlm.nih.gov/27128225/
  89. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1605033/full
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC12486408/
  91. https://pubmed.ncbi.nlm.nih.gov/16551570/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC39831/
  93. https://pubs.rsc.org/en/content/getauthorversionpdf/c8fo00971f
  94. https://pubmed.ncbi.nlm.nih.gov/19699643/
  95. https://www.sciencedirect.com/science/article/abs/pii/S089990071830488X
  96. https://www.mayoclinic.org/drugs-supplements-coenzyme-q10/art-20362602
  97. https://www.webmd.com/vitamins/ai/ingredientmono-938/coenzyme-q10
  98. https://lpi.oregonstate.edu/mic/dietary-factors/coenzyme-q10
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC9759150/
  100. https://www.clinicaltherapeutics.com/article/S0149-2918(24)00414-4/abstract
  101. https://www.sciencedirect.com/science/article/pii/S2772487525000625
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC11515203/
  103. https://pubmed.ncbi.nlm.nih.gov/16846822/
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC11939526/
  105. https://pubmed.ncbi.nlm.nih.gov/30428123/
  106. https://www.news-medical.net/news/20250916/CoQ10-shows-promise-in-boosting-female-fertility-by-reviving-aging-eggs.aspx
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC7550497/
  108. https://www.mdpi.com/2076-3921/12/2/533
  109. https://pubmed.ncbi.nlm.nih.gov/38105612/
  110. https://pubmed.ncbi.nlm.nih.gov/21297042/
  111. https://pubmed.ncbi.nlm.nih.gov/23199523/
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC4226312/
  113. https://jamanetwork.com/journals/jamaneurology/fullarticle/1851409
  114. https://www.neurology.org/doi/10.1212/01.wnl.0000250355.28474.8e
  115. https://www.ncbi.nlm.nih.gov/books/NBK603562/
  116. https://www.merckmanuals.com/home/special-subjects/dietary-supplements-and-vitamins/coenzyme-q10-coq10
  117. https://www.aafp.org/pubs/afp/issues/2005/0915/p1065.html
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC5807419/
  119. https://journals.lww.com/10.1097/CRD.0000000000001056
  120. https://www.webmd.com/vitamins/ai/ingredientmono-834/acetyl-l-carnitine
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC9609170/
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC7482328/
  123. https://www.pharmanord.com/history-coenzyme-Q10-research
  124. https://www.sciencedirect.com/science/article/pii/S0735109707010546
  125. https://www.sciencedirect.com/science/article/abs/pii/S2405457724000184
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC12425901/
  127. https://www.researchgate.net/publication/383175413_The_Role_of_Coenzyme_Q10_in_Skin_Aging_and_Opportunities_for_Topical_Intervention_A_Review
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC12430131/
  129. https://onlinelibrary.wiley.com/doi/10.1002/mnfr.70019
  130. https://www.nature.com/articles/s43856-025-01000-8
  131. https://www.bmj.com/content/387/bmj-2024-081318
  132. https://www.mdpi.com/2227-9032/10/3/487
  133. https://www.lidsen.com/journals/icm/icm-05-04-042
Add your contribution
Related Hubs
User Avatar
No comments yet.